What preventive and acute management should be offered for a patient with weekly migraines?

Management of Weekly Migraines

For a patient experiencing weekly migraines, you should initiate preventive therapy immediately while optimizing acute treatment, as weekly attacks clearly meet the threshold of ≥4 migraine days per month that mandates prevention. 1

Preventive Therapy (Primary Focus)

First-Line Options - Strong Recommendations

With weekly migraines, preventive therapy is not optional—it's indicated. The 2024 VA/DoD guidelines provide the strongest evidence for:

CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) receive "strong for" recommendations based on network meta-analysis of 6,979 patients demonstrating significant reductions in mean monthly migraine days and acute medication use 1. These agents:

• Work faster than traditional oral preventives
• May not require titration
• Show efficacy in both episodic and chronic migraine
• Caution: Erenumab has postmarketing reports of new-onset or worsening hypertension—monitor blood pressure 1

Oral gepants (atogepant) are also newly recommended for prevention 1, offering an alternative mechanism targeting CGRP.

Traditional First-Line Preventives

If CGRP-targeted therapies are unavailable due to cost or access:

• Beta-blockers: Propranolol or metoprolol 2, 3
• Antiseizure medications: Topiramate or valproate 2, 3
• Tricyclic antidepressants: Amitriptyline 2, 3
• Calcium channel blockers: Flunarizine (where available) 2

Titration and Trial Duration

• Traditional oral preventives: Start low, titrate slowly to therapeutic dose
• Allow 2-3 months at adequate dose before declaring failure 4
• CGRP monoclonal antibodies: Assess efficacy after 3-6 months 4
• Failure of one class does not predict failure of another 4

Acute Treatment Optimization

First-Line Acute Medications

NSAIDs should be first-line: acetylsalicylic acid, ibuprofen, or diclofenac potassium 4

Triptans are second-line for moderate-to-severe attacks 4. Consider combining triptans with fast-acting NSAIDs to prevent recurrence 4.

Gepants and ditans (lasmiditan) are third-line acute options 4. Note that lasmiditan carries driving restrictions for at least 8 hours post-dose 4.

Critical Acute Treatment Principles

• Treat early in the headache phase—effectiveness depends on timely use with correct dosing 4
• Use stratified approach based on attack severity 1
• Goal: Return to full function within 2 hours 5

Adjunct Therapy

For nausea/vomiting: Use prokinetic antiemetics (domperidone or metoclopramide) before NSAIDs/triptans 4, 2

Medications to AVOID

Do not use 4:

• Oral ergot alkaloids (poorly effective, potentially toxic)
• Opioids (questionable efficacy, dependency risk)
• Barbiturates (adverse effects, dependency risk)

Medication Overuse Prevention

Critical pitfall: With weekly migraines, there's substantial risk of medication overuse headache (MOH). Counsel the patient that:

• Frequent, repeated use of acute medications risks MOH development 4
• This is a key reason preventive therapy is essential at this frequency
• Limit acute medication use to <10 days/month for triptans, <15 days/month for NSAIDs

Algorithmic Approach

1. Initiate preventive therapy immediately (≥4 migraine days/month is the threshold) 1
2. Choose CGRP monoclonal antibody if accessible (strongest evidence, "strong for" recommendation) 1
3. If CGRP agents unavailable: Select from beta-blockers, topiramate, valproate, or amitriptyline based on comorbidities
4. Optimize acute treatment: NSAIDs first-line, triptans second-line, treat early 4
5. Add antiemetic if nausea present 4
6. Monitor for medication overuse and adjust if developing MOH
7. Reassess after adequate trial: 2-3 months for oral preventives, 3-6 months for CGRP antibodies 4
8. If first preventive fails: Switch to different drug class 4

Additional Considerations

Neuromodulation devices may be appropriate for patients preferring non-drug therapies or with contraindications/poor tolerance to pharmacotherapy 6.

Greater occipital nerve blocks can be considered for both acute and preventive management, with favorable risk-benefit profile and ease of administration in outpatient settings 1.